Zacks Investment Research upgraded Theravance Biopharma Inc (NASDAQ:TBPH) to Hold in a report released today.
- Updated: October 14, 2016
Just yesterday Theravance Biopharma Inc (NASDAQ:TBPH) traded -8.88% lower at $31.25. Theravance Biopharma Inc’s 50-day moving average is $33.14 and its 200-day moving average is $25.33. The last stock price is up 14.61% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 685,248 shares of TBPH traded hands, up from an average trading volume of 242,689
Zacks Investment Research has upgraded Theravance Biopharma Inc (NASDAQ:TBPH) to Hold in a report released on 10/14/2016.
Recent Performance Chart
Theravance Biopharma Inc has 52 week low of $12.87 and a 52 week high of $38.92 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its target, a total of 1 equity analyst has released a research note on the stock. The consensus target price is $19.00 with 1 firm rating the stock a strong buy, 0 brokerages rating the stock a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.
More About Theravance Biopharma Inc (NASDAQ:TBPH)
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.